3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
2
Status
Recruiting
1
Not yet recruiting
1
Sponsor Class
OTHER
2
Study Type
Interventional
2
Sponsor
Cancer Type
Head & Neck
118
Endocrine
118
Thoracic
19
Gastrointestinal
19
CNS
17
Genitourinary
14
Gynecologic
11
Dermatologic
11
Breast
10
Sarcoma
6
Lymphoid
4
Other hematologic neoplasm
3
NET
3
Plasma cell
2
Other solid neoplasm
2
Myeloid
2
Conditions
Multiple Myeloma
3082
Neoplasms, Plasma Cell
614
Lymphoma
455
Lymphoma, Non-Hodgkin
428
Recurrence
371
Hodgkin Disease
366
Leukemia, Lymphocytic, Chronic, B-Cell
362
Precursor Cell Lymphoblastic Leukemia-Lymphoma
340
Leukemia, Myeloid, Acute
322
Leukemia
321
Myelodysplastic Syndromes
287
Lymphoma, Mantle-Cell
262
Lymphoma, Large B-Cell, Diffuse
259
Lymphoma, Follicular
254
Lymphoma, B-Cell, Marginal Zone
231
Burkitt Lymphoma
227
Lymphoma, Large-Cell, Immunoblastic
203
Myeloproliferative Disorders
197
Immunoglobulin Light-chain Amyloidosis
184
Neoplasms
182
Hematologic Neoplasms
169
Primary Myelofibrosis
167
Leukemia, Myeloid, Chronic-Phase
165
Leukemia, Myeloid, Accelerated Phase
154
Lymphoma, T-Cell, Cutaneous
150
Waldenstrom Macroglobulinemia
145
Blast Crisis
143
Leukemia, Myelomonocytic, Chronic
140
Mycosis Fungoides
129
Sezary Syndrome
128
Interventions
trametinib
1
dabrafenib
1
cobimetinib
1
Vemurafenib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Interventional
×
Thyroid Cancer, Papillary
×
Plasma cell
×
Clear all
NCT07440290
2026-02-27
DETERMINE
Cancer Research UK
Phase 2/3
Not yet recruiting
30 enrolled
NCT05768178
2025-11-24
DETERMINE
Cancer Research UK
Phase 2/3
Recruiting
30 enrolled